 MINNEAPOLIS, Feb. 23, 2021 GLOBE NEWSWIRE -- Predictive Oncology Inc. NASDAQ: POAI Predictive Oncology or the Company, a knowledge-driven company focused on applying artificial intelligence AI to personalized medicine and drug discovery, today announced the closing of its previously announced private placement of common stock and warrants priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of 17,635,343.70. The Company sold and issued an aggregate of 9,043,766 shares of its common stock and warrants to purchase up to an aggregate of 4,521,883 shares of common stock in the private placement, at a purchase price of 1.95 per share of common stock and associated warrant. The warrants have an exercise price of 2.00 per share, are exercisable immediately and have a term of five and one-half years. 